Innovations in Heart Rhythm Treatments for LA Patients
There are still new developments in the way we treat heart rhythm problems, giving patients more accurate ways to find problems and more alternatives for treatment. If you’re looking for a top electrophysiologist in Los Angeles, you likely want care that blends a doctor’s clinical experience with the latest in medical technology. The Cardiac Electrophysiology Institute (CEPI) has dedicated electrophysiology specialists who use proven methodologies and specialized treatment strategies to address the individual heart health needs of each patient.Every approach described here is in active clinical use. What has changed is the precision with which arrhythmias can be mapped, the expanded capabilities of cardiac devices in both treatment and monitoring, and newer options for patients who cannot tolerate standard long-term approaches to stroke prevention.
How the Approach to Catheter Ablation Has Changed
Catheter ablation has been used to treat arrhythmias for decades. What has evolved is how precisely the arrhythmia source can be located and how consistently ablation can address it. Three-dimensional electroanatomic mapping systems now allow an electrophysiologist to build a real-time, detailed map of the heart’s electrical activity from inside the chamber walls. This makes it possible to identify exactly where abnormal signals originate and confirm that the ablation has addressed the source, rather than relying on anatomical landmarks alone.
For AFib specifically, the introduction of cryoablation (using extreme cold rather than radiofrequency heat to create scar tissue) has expanded options. Both radiofrequency and cryoablation are used depending on the patient’s anatomy, the type of AFib, and other clinical factors. Neither technique is universally superior. The right choice is made individually based on each patient’s anatomy and clinical picture.
Improved catheter design and contact-force sensing technology also mean ablation lesions can be placed more consistently, reducing the chance that the arrhythmia recurs from a gap in the scar. Patients who had an ablation several years ago and continue to have symptoms may be candidates for a repeat procedure using current-generation equipment and mapping technology.
Next-Generation Cardiac Devices
Pacemakers and ICDs have become smaller, more capable, and in some configurations, entirely wireless. Leadless pacemakers are implanted directly into the heart chamber without the traditional wire leads that run through blood vessels. For patients where lead complications are a concern, this represents a meaningful alternative to standard device implantation.
Subcutaneous ICDs offer another shift in device options. Unlike traditional ICDs, which have leads inside the heart, a subcutaneous ICD is placed entirely under the skin, outside the heart and blood vessels. This eliminates the risks associated with intravascular leads while still providing life-saving defibrillation capability. Not every patient is a candidate, but for the right individual, this option avoids a significant source of long-term device complications.
Remote monitoring capabilities in modern devices have also improved considerably. Current-generation pacemakers and ICDs transmit data automatically, flag arrhythmia events without patient action, and allow programming adjustments without requiring an in-person visit in some cases. For patients managing ventricular tachycardia (VT) alongside a device, this kind of continuous data transmission provides a level of oversight that periodic office visits alone cannot match.
The Watchman Device: A Newer Approach to Stroke Prevention
For patients with non-valvular AFib who cannot safely take long-term anticoagulants, the Watchman device offers a structural answer to what is otherwise a pharmacological problem. Most AFib-related blood clots form in the left atrial appendage, a small pouch in the upper left chamber of the heart. The Watchman is a small implant placed inside the appendage to seal it off, preventing clots from entering the bloodstream.
The procedure is minimally invasive and is performed in a catheterization lab under sedation. Most patients transition off long-term anticoagulation within 45 to 90 days as the device becomes incorporated into the heart tissue. The Watchman is particularly relevant for patients who have experienced significant bleeding on blood thinners or who carry a high bleeding risk alongside their AFib diagnosis.
The Watchman does not treat the AFib rhythm itself. It is a stroke prevention tool. Some patients choose the Watchman alongside ablation as part of a broader AFib management plan. Eligibility is evaluated individually based on each patient’s stroke and bleeding risk profile.
Wearable Technology and Earlier Arrhythmia Detection
Consumer wearable devices have become a real part of clinical cardiology, not because they replace diagnostic equipment, but because they have brought patients into care who would not otherwise have known their rhythm was abnormal. The AFib detection algorithms in devices like the Apple Watch and Kardia have been validated in clinical research, and a repeated irregular rhythm alert on a verified wearable is a reasonable prompt for formal evaluation.
In practice, this means we are now seeing patients earlier in their AFib course, often before the arrhythmia has become persistent or before structural changes in the atrium have occurred. Earlier evaluation means more options, because paroxysmal AFib generally responds better to ablation than persistent AFib does.
If your wearable device has flagged an irregular rhythm on more than one occasion, that is worth following up with an extended monitor or a formal consultation. Waiting to see if the alert recurs is not the same as ruling out a real arrhythmia.
What These Advances Mean for Patients in Los Angeles
Better technology does not automatically translate to better care. It does in the hands of a physician who uses it regularly and knows when it is and is not appropriate. At CEPI, our practice is focused entirely on rhythm disorders. Every patient we see has a rhythm-related condition, which means the full scope of what electrophysiology offers is applied to every evaluation.
Dr. Arshia M. Noori, MD, FACC, FHRS holds triple board certification from the American Board of Internal Medicine (ABIM) in Clinical Cardiac Electrophysiology, Cardiovascular Disease, and Internal Medicine. His published research on the molecular mechanisms of AFib and the effects of autonomic stimulation on atrial electrophysiology after ablation reflects an academic approach to clinical practice that informs how complex and treatment-resistant cases are managed.
For patients in Los Angeles with a rhythm disorder, whether newly diagnosed or years into management, we welcome a direct inquiry. No referral is needed.
Related Topics: